Research programme: AMPA receptor antagonists - Purdue Pharma/Senju

Drug Profile

Research programme: AMPA receptor antagonists - Purdue Pharma/Senju

Latest Information Update: 03 Sep 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Purdue Pharma
  • Developer Purdue Pharma; Senju Pharmaceutical
  • Class
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Epilepsy; Eye disorders; Pain; Schizophrenia; Stroke

Most Recent Events

  • 16 Nov 1999 CoCensys has been acquired by Purdue Pharma
  • 16 Mar 1999 CoCensys has entered into a research agreement with Senju
  • 16 Mar 1999 Preclinical development for Eye disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top